A blood sample was collected in the morning before surgery, placed in a chilled tube containing aprotinin (500 KIU/ml) and EDTA (1.2 mg/ml), and immediately centrifuged. The plasma thus obtained was diluted five-fold with 4% acetic acid (pH 4.0), and loaded onto a column with a C18 reversed-phase cartridge (Sep-Pak C18, Millipore, Milford, MA, USA). After washing with 4% acetic acid, peptides were eluted with 70% acetonitrile in 0.5% acetic acid (pH 4.0). The eluted samples were concentrated by spin-vacuum evaporation, lyophilized, and stored at -40°C until assay. EIA was performed by the delayed-addition method with separation of bound and free antigens on anti-rabbit IgG-coated immunoplates.

Human metastin (45–54) was conjugated with β-D-galactosidase using N -(ε-maleimidocaproyloxy)-succinimide, as reported previously[27]. The EIA was sensitive and specific LY333531 chemical structure for all bioactive KiSS-1 gene products (metastin, kisspeptin-14, and kisspeptin-13)[25]. The third quartile value was set as a cut-off for the plasma metastin level. We evaluated the association between the plasma level of metastin SB202190 research buy and metastin immunoreactivity in resected pancreatic cancer tissues, and also the associations between plasma metastin and the clinicopathological characteristics of the patients. Statistical analysis Continuous variables are presented as the mean ± standard deviation or as the

median and range. Comparison of the groups was done with the Mann-Whitney U test, while categorical variables were compared by the χ2 test. Correlations between metastin and GPR54 immunoreactivity were investigated by calculation of Pearson’s correlation coefficient (r) values and scatter plots with a linear regression line were drawn. An r value of 0–0.19 was defined as a very weak correlation, while 0.2–0.39 was weak, 0.40–0.59 was moderate, 0.6–0.79 was strong, and 0.8–1 was very strong. Overall survival curves were drawn by the Kaplan-Meier Morin Hydrate method, and were compared by the log-rank test. Prognostic factors for survival were examined by univariate and multivariate analyses using Cox’s proportional hazards model. For all analyses, p < 0.05

was considered to be statistically significant. Results Demographic and clinicopathological characteristics There were 25 men (47.2%) and 28 women (52.8%) with a mean age at diagnosis of 65.6 years (median age: 68 years; range: 32 – 86 years). The tumor was located in the head of the pancreas in 38 patients (71.7%), while it was found in the distal pancreas in 15 patients (28.3%). Pancreatoduodenectomy was performed in 36 patients (67.9%), while distal Mdivi1 manufacturer pancreatectomy was performed in 13 patients (24.5%), and total pancreatectomy in 4 patients (7.5%). On histopathological examination, one patient (1.9%) had pStage IA disease, three patients (5.7%) had pStage IB, 16 patients (30.2%) had pStage IIA, 29 patients (54.7%) had pStage IIB, and four patients (7.5%) had pStage IV.